$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm

$atnm Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025597 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$0.00	$1.030M
YoY Change		-100.0%	-9.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.735M	$3.958M	$11.99M
YoY Change	115.27%	49.08%	48.73%
% of Gross Profit
Research & Development	$7.849M	$7.333M	$23.14M
YoY Change	79.65%	35.4%	28.94%
% of Gross Profit
Depreciation & Amortization	$182.0K	$161.0K	$152.0K
YoY Change	32.85%	17.52%	-70.99%
% of Gross Profit
Operating Expenses	$11.58M	$11.29M	$35.13M
YoY Change	89.78%	39.9%	34.57%
Operating Profit	-$11.58M		-$34.10M
YoY Change	124.32%		36.61%
Interest Expense	$547.0K	$644.0K	$1.087M
YoY Change	1462.86%	1594.74%	472.11%
% of Operating Profit
Other Income/Expense, Net	$547.0K		$1.087M
YoY Change	1462.86%		472.11%
Pretax Income	-$11.04M	-$10.65M	-$33.02M
YoY Change	115.19%	32.92%	33.27%
Income Tax
% Of Pretax Income
Net Earnings	-$11.04M	-$10.65M	-$33.02M
YoY Change	115.19%	32.92%	33.27%
Net Earnings / Revenue			-3205.53%
Basic Earnings Per Share	-$0.43		-$1.37
Diluted Earnings Per Share	-$0.43	-$0.42	-$1.37
COMMON SHARES
Basic Shares Outstanding	25.73M shares	25.48M shares	24.14M shares
Diluted Shares Outstanding	25.70M shares		24.14M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.52M	$108.9M	$108.9M
YoY Change	31.25%	39.93%	39.93%
Cash & Equivalents	$94.52M	$108.9M	$108.9M
Short-Term Investments
Other Short-Term Assets	$4.024M	$2.032M	$2.032M
YoY Change	97.84%	5.83%	5.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$98.55M	$110.9M	$110.9M
YoY Change	33.07%	39.11%	39.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$630.0K	$604.0K	$2.948M
YoY Change	23.77%	77.65%	361.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$304.0K	$302.0K	$302.0K
YoY Change
Total Long-Term Assets	$3.480M	$3.250M	$3.250M
YoY Change	583.69%	408.61%	408.61%
TOTAL ASSETS
Total Short-Term Assets	$98.55M	$110.9M	$110.9M
Total Long-Term Assets	$3.480M	$3.250M	$3.250M
Total Assets	$102.0M	$114.2M	$114.2M
YoY Change	36.83%	42.05%	42.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.358M	$10.13M	$10.13M
YoY Change	39.86%	83.02%	83.02%
Accrued Expenses	$503.0K	$494.0K	$494.0K
YoY Change	226.62%	101.63%	101.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.000K	$4.000K	$4.000K
YoY Change	-92.68%	-93.55%	-93.55%
Total Short-Term Liabilities	$7.864M	$10.63M	$10.63M
YoY Change	37.41%	55.38%	55.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$36.95M	$37.08M	$37.08M
YoY Change
Total Long-Term Liabilities	$36.95M	$37.08M	$37.08M
YoY Change	1847600.0%	1236000.0%	1236000.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.864M	$10.63M	$10.63M
Total Long-Term Liabilities	$36.95M	$37.08M	$37.08M
Total Liabilities	$44.82M	$47.71M	$47.71M
YoY Change	682.85%	597.22%	597.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$299.8M	-$288.8M
YoY Change		12.91%
Common Stock	$26.00K	$26.00K
YoY Change		18.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$57.21M	$66.48M	$66.48M
YoY Change
Total Liabilities & Shareholders Equity	$102.0M	$114.2M	$114.2M
YoY Change	36.83%	42.05%	42.05%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$11.04M	-$10.65M	-$33.02M
YoY Change	115.19%	32.92%	33.27%
Depreciation, Depletion And Amortization	$182.0K	$161.0K	$152.0K
YoY Change	32.85%	17.52%	-70.99%
Cash From Operating Activities	-$15.08M	-$7.778M	$8.644M
YoY Change	160.8%	53.96%	-141.43%
INVESTING ACTIVITIES
Capital Expenditures	$76.00K	$16.00K	$366.0K
YoY Change	-1185.71%		-375.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$76.00K	-$16.00K	-$366.0K
YoY Change	985.71%		175.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$770.0K	4.893M	$23.11M
YoY Change	-3600.0%	510.86%	-34.39%
NET CHANGE
Cash From Operating Activities	-$15.08M	-7.778M	$8.644M
Cash From Investing Activities	-$76.00K	-16.00K	-$366.0K
Cash From Financing Activities	$770.0K	4.893M	$23.11M
Net Change In Cash	-$14.38M	-2.901M	$31.39M
YoY Change	147.56%	-31.76%	120.69%
FREE CASH FLOW
Cash From Operating Activities	-$15.08M	-$7.778M	$8.644M
Capital Expenditures	$76.00K	$16.00K	$366.0K
Free Cash Flow	-$15.15M	-$7.794M	$8.278M
YoY Change	162.44%	54.28%	-139.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24141545	shares
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-52446
CY2022	dei	Entity Registrant Name EntityRegistrantName	ACTINIUM PHARMACEUTICALS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	74-2963609
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	275 Madison Avenue, 7th Fl
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10016
CY2022	dei	City Area Code CityAreaCode	(646)
CY2022	dei	Local Phone Number LocalPhoneNumber	677-3870
CY2022	dei	Security12b Title Security12bTitle	Common stock, par value $0.001
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Trading Symbol TradingSymbol	ATNM
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q2	dei	Entity Public Float EntityPublicFloat	119589361	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25729370	shares
CY2022	dei	Auditor Name AuditorName	Marcum llp
CY2022	dei	Auditor Location AuditorLocation	Houston, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108910000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77829000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	396000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	392000	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	50000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1636000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1478000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	110942000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	79749000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	487000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	335000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	604000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	340000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	302000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2341000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	241000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	58000	usd
CY2022Q4	us-gaap	Assets Assets	114192000	usd
CY2021Q4	us-gaap	Assets Assets	80388000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	10130000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	5535000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	998000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	494000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	62000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10628000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6840000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	35000000	usd
CY2022Q4	atnm	Longterm Operating Lease Obligations Noncurrent LongtermOperatingLeaseObligationsNoncurrent	2083000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	47711000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6843000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25674823	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25674823	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22143974	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22143974	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	26000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	22000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	355220000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	329271000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288765000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-255748000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	66481000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	73545000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	114192000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80388000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	1030000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	1144000	usd
CY2022	us-gaap	Revenues Revenues	1030000	usd
CY2021	us-gaap	Revenues Revenues	1144000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23135000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18031000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11999000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8077000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	35134000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	26108000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34104000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-24964000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1087000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	190000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1087000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	190000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33017000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24774000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.2
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24141545	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20568373	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	61319000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1694000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	35300000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24774000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73545000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2795000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	23158000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33017000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66481000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33017000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-24774000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2795000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1694000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	699000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	524000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	158000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	161000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4595000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1195000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-998000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	998000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	35000000	usd
CY2022	atnm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-272000	usd
CY2021	atnm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-342000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8644000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20866000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	366000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-366000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	49000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	85000	usd
CY2022	atnm	Sales Of Shares Of Common Stock Net Of Costs SalesOfSharesOfCommonStockNetOfCosts	23158000	usd
CY2021	atnm	Sales Of Shares Of Common Stock Net Of Costs SalesOfSharesOfCommonStockNetOfCosts	35300000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23109000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35221000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31387000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14222000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78221000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63999000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109608000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78221000	usd
CY2022	atnm	Rightofuse Assets Obtained In Exchange For Lease Liabilities RightofuseAssetsObtainedInExchangeForLeaseLiabilities	2605000	usd
CY2022	atnm	Acquisition Of Equipment Financed By Security Deposit AcquisitionOfEquipmentFinancedBySecurityDeposit	50000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in Financial Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	108910000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	77829000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	396000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	392000	usd
CY2022Q4	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	302000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	109608000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	78221000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5164	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3474	shares
CY2022	atnm	Accountingstandardsrecentlyissuedpolicytextblock Accountingstandardsrecentlyissuedpolicytextblock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting Pronouncements – </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718) and Derivatives and Hedging – Contracts in an Entity’s Own Equity (Subtopic 815-40) – Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company’s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company’s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	684000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	874000	usd
CY2022Q4	atnm	Prepaid Clinical Trial Expenses PrepaidClinicalTrialExpenses	887000	usd
CY2021Q4	atnm	Prepaid Clinical Trial Expenses PrepaidClinicalTrialExpenses	543000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	65000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	61000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1636000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1478000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	487000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	335000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	604000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	340000	usd
CY2022	us-gaap	Depreciation Depreciation	152000	usd
CY2021	us-gaap	Depreciation Depreciation	105000	usd
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	5 years 2 months
CY2022	us-gaap	Lease Cost LeaseCost	600000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	584000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	372000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	55000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	81000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	57000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	90000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	352000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	377000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	9000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	49000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	85000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2605000	usd
CY2022	atnm	Schedule Or Description Of Weighted Average Term ScheduleOrDescriptionOfWeightedAverageTerm	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td>Weighted average remaining lease term:</td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 90%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 years</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance Leases</td><td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022	atnm	Schedule Of Weighted Average Discount Rate ScheduleOfWeightedAverageDiscountRate	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>Weighted average discount rates:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.048	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022	atnm	Recognition Of Deferred Revenue1 RecognitionOfDeferredRevenue1	900000	usd
CY2021	atnm	Recognition Of Deferred Revenue1 RecognitionOfDeferredRevenue1	900000	usd
CY2022	atnm	Revenue Recognized RevenueRecognized	100000	usd
CY2021	atnm	Revenue Recognized RevenueRecognized	200000	usd
CY2022Q2	atnm	Upfront Payment UpfrontPayment	35000000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1000000	usd
CY2022Q4	atnm	Longterm License Revenue Deferred LongtermLicenseRevenueDeferred	35000000	usd
CY2012Q2	atnm	Milestone Payment MilestonePayment	1000000	usd
CY2012Q2	atnm	Description Of Royalty Payment To Related Party DescriptionOfRoyaltyPaymentToRelatedParty	Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	91666	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	758333	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	815	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.53
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M3D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	120000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	881	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.43
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.69
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	333	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.78
CY2017Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	22.5
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1362	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.45
CY2021	atnm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y8M8D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2094	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	60	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	12.9
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3396	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8
CY2022	atnm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y10M6D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	15204000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	804	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.3
CY2022	atnm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted	P7Y6M29D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2432000	usd
CY2022	atnm	Grant Of Stock Options Purchase Shares GrantOfStockOptionsPurchaseShares	2100000	shares
CY2022	atnm	Stock Option Term StockOptionTerm	P10Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Dividends Dividends	0	usd
CY2021	atnm	Grant Of Stock Options Purchase Shares GrantOfStockOptionsPurchaseShares	881000	shares
CY2021	atnm	Stock Option Term StockOptionTerm	P10Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Dividends Dividends	0	usd
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	60000	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	333000	shares
CY2021	atnm	Stock Options Exercised Shares Of Common Stock StockOptionsExercisedSharesOfCommonStock	1000	shares
CY2022	atnm	Weighted Average Term WeightedAverageTerm	P3Y3M18D
CY2022	atnm	Compensation Expense Related To Stock Options CompensationExpenseRelatedToStockOptions	2500000	usd
CY2021	atnm	Compensation Expense Related To Stock Options CompensationExpenseRelatedToStockOptions	1500000	usd
CY2022	atnm	Compensation Expense Related To Rs Us CompensationExpenseRelatedToRSUs	200000	usd
CY2022Q3	atnm	Class Of Warrants Shares Expired ClassOfWarrantsSharesExpired	600000	shares
CY2017Q3	atnm	Underwritten Offering Shares UnderwrittenOfferingShares	700000	shares
CY2017Q3	atnm	Warrants To Purchase Shares Of Common Stock warrantsToPurchaseSharesOfCommonStock	600000	shares
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	562000	usd
CY2021	atnm	Effective Income Tax Reconciliation Deferred True Ups EffectiveIncomeTaxReconciliationDeferredTrueUps	0.023	pure
CY2022	atnm	Exercisable Period Years ExercisablePeriodYears	P5Y
CY2022	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	31.5
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44233000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36405000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1334000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1213000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17247000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14536000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	13210000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	10426000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	19000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	76093000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62599000	usd
CY2022Q4	atnm	Deferred Tax Assets Valuation Allowances DeferredTaxAssetsValuationAllowances	76100000	usd
CY2021Q4	atnm	Deferred Tax Assets Valuation Allowances DeferredTaxAssetsValuationAllowances	62600000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies Foreign IncomeTaxReconciliationTaxContingenciesForeign	178600000	usd
CY2022	us-gaap	Tax Credit Carryforward Limitations On Use TaxCreditCarryforwardLimitationsOnUse	NOLs of $118.4 million generated prior to 2018 will begin to expire if unused in 2023. NOLs generated in 2018 and later years of $60.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1, 2023.
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	271100000	usd
CY2022	us-gaap	Research And Development Arrangement With Federal Government Costs Incurred Net ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet	3400000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	13800000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6943000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5202000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4863000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.147	pure
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-373000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.015	pure
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	89000	usd
CY2022	atnm	Effective Income Tax Reconciliation Deferred True Ups EffectiveIncomeTaxReconciliationDeferredTrueUps	0.003	pure
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2711000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.082	pure
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1898000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.077	pure
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	934000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.028	pure
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	486000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.02	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13494000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.408	pure
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6425000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.259	pure
CY2022	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	100000	usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	800000	usd
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022Q4	us-gaap	Security Deposit SecurityDeposit		usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2021Q4	atnm	Longterm Operating Lease Obligations Noncurrent LongtermOperatingLeaseObligationsNoncurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20568373	shares
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	atnm	Rightofuse Assets Obtained In Exchange For Lease Liabilities RightofuseAssetsObtainedInExchangeForLeaseLiabilities		usd
CY2021	atnm	Acquisition Of Equipment Financed By Security Deposit AcquisitionOfEquipmentFinancedBySecurityDeposit		usd
CY2021Q4	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2021Q4	atnm	Longterm License Revenue Deferred LongtermLicenseRevenueDeferred		usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001388320

Files In Submission

Name	View Source	Status
atnm-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-025597-index-headers.html	Edgar Link	pending
0001213900-23-025597-index.html	Edgar Link	pending
0001213900-23-025597.txt	Edgar Link	pending
0001213900-23-025597-xbrl.zip	Edgar Link	pending
atnm-20221231.xsd	Edgar Link	pending
f10k2022ex23-1_actinium.htm	Edgar Link	pending
f10k2022ex31-1_actinium.htm	Edgar Link	pending
f10k2022ex31-2_actinium.htm	Edgar Link	pending
f10k2022ex32-1_actinium.htm	Edgar Link	pending
f10k2022ex32-2_actinium.htm	Edgar Link	pending
f10k2022_actiniumph.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
atnm-20221231_def.xml	Edgar Link	unprocessable
atnm-20221231_lab.xml	Edgar Link	unprocessable
atnm-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_actiniumph_htm.xml	Edgar Link	completed
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm

2023 Q1 Form 10-K Financial Statement

#000121390023025597 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNM Actinium Pharmaceuticals, Inc. Stock $atnm

2023 Q1 Form 10-K Financial Statement

#000121390023025597 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm